-
EP4534088
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP Citations: EP4534088
| Cited in | Search | Type: | Patent literature | Publication No.: | US2023116137
[A] (GANLÖV KARIN et al.) | Type: | Patent literature | Publication No.: | US2023097085
[A] (TELL ROGER INGVAR et al.) | Type: | Patent literature | Publication No.: | US2023095428
[A] (TELL ROGER INGVAR et al.) | Type: | Non-patent literature | Publication information: | [I] ANONYMOUS: "Clinical Trial NCT03750786: A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer", 23 November 2018 (2018-11-23), XP093132848, Retrieved from the Internet | Type: | Non-patent literature | Publication information: | [A] CARLSSON G. ET AL: "A phase I/II study of arfolitixorin and 5-fluorouracil in combination with oxaliplatin (plus or minus bevacizumab) or irinotecan in metastatic colorectal cancer", ESMO OPEN : CANCER HORIZONS, vol. 7, no. 5, 1 October 2022 (2022-10-01), London, pages 100589, XP093082930, ISSN: 2059-7029, DOI: 10.1016/j.esmoop.2022.100589 | DOI: | http://dx.doi.org/10.1016/j.esmoop.2022.100589 | Type: | Non-patent literature | Publication information: | [AD] ANONYMOUS: "Clinical Trial NCT04126655: Modelle 001, TS-inhibition in Colorectal Liver Metastases Comparing Arfolitixorin and Calciumfolinate", 27 August 2020 (2020-08-27), XP093132889, Retrieved from the Internet | Type: | Non-patent literature | Publication information: | [A] ANON.: "Equivalent Surface Area Dosage Conversion Factors", 1 August 2007 (2007-08-01), XP093132885, Retrieved from the Internet | Cited in | by applicant | Type: | Patent literature | Publication No.: | WO2019037898
| Type: | Patent literature | Publication No.: | WO2019037899
| Type: | Non-patent literature | Publication information: | KOVOOR ET AL., CLIN COLORECTAL CANCER, vol. 8, 2009, pages 200 - 6 | Type: | Non-patent literature | Publication information: | TAFLIN: "Modelle 001, TS-inhibition in Colorectal Liver Metastases Comparing Arfolitixorin and Calciumfolinate", STUDY DETAILS, 2023 | Type: | Non-patent literature | Publication information: | F CAPUTO: "BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights", J. MOL. SCI., vol. 20, 2019, pages 5369 | Type: | Non-patent literature | Publication information: | F BRAY ET AL.: "Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA CANCER J. CLIN., vol. 68, 2018, pages 394 - 424 | Type: | Non-patent literature | Publication information: | P V DANENBERG ET AL.: "Folates as adjuvants to anticancer agents: Chemical rationale andmechanism of action", CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY, vol. 106, 2016, pages 118 - 131, XP029727888, DOI: 10.1016/j.critrevonc.2016.08.001 | DOI: | http://dx.doi.org/10.1016/j.critrevonc.2016.08.001 | Type: | Non-patent literature | Publication information: | C CREMOLINI: "Metastatic Colorectal Cancer", JOURNAL OF CLINICAL ONCOLOGY, vol. 38, no. 28, August 2020 (2020-08-01) | Type: | Non-patent literature | Publication information: | K VAN DER JEUGHT ET AL.: "Drug resistance and new therapies in colorectal cancer", WORLD J GASTROENTEROL, vol. 24, no. 34, 14 September 2018 (2018-09-14), pages 3834 - 3848 | Type: | Non-patent literature | Publication information: | J D FINKLE ET AL.: "Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNA", NPJ PRECIS. ONE., vol. 5, 2021, pages 63, XP055843717, DOI: 10.1038/s41698-021-00202-2 | DOI: | http://dx.doi.org/10.1038/s41698-021-00202-2 | Type: | Non-patent literature | Publication information: | J B BACHET ET AL.: "RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study", ANN ONCOL., vol. 29, no. 5, 1 May 2018 (2018-05-01), pages 1211 - 1219 | Type: | Non-patent literature | Publication information: | A.TSUJI ET AL.: "The randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors: The DEEPER trial (JACCRO CC-13", JOURNAL OF CLINICAL ONCOLOGY, vol. 39, no. 15, 20 May 2021 (2021-05-20), pages 3501 - 3501 | Type: | Non-patent literature | Publication information: | G PATELLI ET AL.: "Strategies to tackle RAS-mutated metastatic colorectal cancer", ESMO OPEN CANCER HORIZONS, vol. 6, 2021, Retrieved from the Internet | Type: | Non-patent literature | Publication information: | OECD/WORLD HEALTH ORGANIZATION: "Health at a Glance: Asia/Pacific 2018: Measuring Progress towards Universal Health Coverage", 2018, OECD PUBLISHING, article "Five-year net survival for breast, cervical and colorectal cancer" | Type: | Non-patent literature | Publication information: | ALKADER M S ET AL.: "Impact of KRAS Mutation on Survival Outcome of Patients With Metastatic Colorectal Cancer in Jordan", CUREUS, vol. 15, no. 1, 13 January 2023 (2023-01-13), pages e33736, Retrieved from the Internet | Type: | Non-patent literature | Publication information: | J DIERKES ET AL.: "Folic acid and Vitamin B6 supplementation and plasma homocysteine concentrations in healthy young women", INT J VITAM NUTR RES, vol. 68, no. 2, 1998, pages 98 - 103 | Type: | Non-patent literature | Publication information: | B SHANE: "Food and Nutrition Bulletin", vol. 29, 2008, THE UNITED NATIONS UNIVERSITY, article "Folate and vitamin B12 metabolism: Overview and interaction with riboflavin, vitamin B6, and polymorphisms" | Type: | Non-patent literature | Publication information: | Y SONG ET AL.: "Effect of Combined Folic Acid, Vitamin B6, and Vitamin B12 on Colorectal Adenoma", J NATL CANCER INST, vol. 104, 2012, pages 1562 - 1575, XP093083147, DOI: 10.1093/jnci/djs370 | DOI: | http://dx.doi.org/10.1093/jnci/djs370 | Type: | Non-patent literature | Publication information: | XH ZHANG ET AL.: "Vitamin B6 and colorectal cancer: Current evidence and future directions", WORLD J GASTROENTEROL, vol. 19, no. 7, 2013, pages 1005 - 1010, XP093083165, DOI: 10.3748/wjg.v19.i7.1005 | DOI: | http://dx.doi.org/10.3748/wjg.v19.i7.1005 | Type: | Non-patent literature | Publication information: | D MACHOVER ET AL.: "Pharmacologic modulation of 5-fluorouracil by folinic acid and pyridoxine for treatment of patients with advanced breast carcinoma", SCIENTIFIC REPORTS, vol. 12, 2022, pages 9079, XP093083166, DOI: 10.1038/s41598-022-12998-5 | DOI: | http://dx.doi.org/10.1038/s41598-022-12998-5 | Type: | Non-patent literature | Publication information: | D MACHOVER ET AL.: "Pharmacologic modulation of 5-fluorouracil by folinic acid and high-dose pyridoxine for treatment of patients with digestive tract carcinomas", SCIENTIFIC REPORTS, vol. 11, 2021, pages 12668, XP093083546, DOI: 10.1038/s41598-021-92110-5 | DOI: | http://dx.doi.org/10.1038/s41598-021-92110-5 | Type: | Non-patent literature | Publication information: | D MACHOVER ET AL.: "Enhancement of 5-fluorouracil cytotoxicity by pyridoxal 5'-phosphate and folinic acid in tandem", J. PHARMACOL. EXP. THER., vol. 366, 2018, pages 238 - 243, XP093053954, DOI: 10.1124/jpet.118.249367 | DOI: | http://dx.doi.org/10.1124/jpet.118.249367 | Type: | Non-patent literature | Publication information: | Y WONG: " Long-Term Survival of De Novo Stage IV HER2 Positive Breast Cancers", THE ONCOLOGIST, vol. 24, 2019, pages 313 - 318 | Type: | Non-patent literature | Publication information: | TAFLIN ET AL.: "8th International Symposium on Folate Biology and Therapeutics", 4 October 2023, EDITH MACY CENTER BRIARCLIFF MANOR, article "Thymidylate synthase inhibition in colorectal liver metastases can be improved with Arfolitixorin compared to Leucovorin" |